Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mamiko Kawasaki"'
Autor:
Tadaaki Nishikawa, Kosei Hasegawa, Koji Matsumoto, Masahiko Mori, Yasuyuki Hirashima, Kazuhiro Takehara, Kazuya Ariyoshi, Tomoyasu Kato, Shigehiro Yagishita, Akinobu Hamada, Mamiko Kawasaki, Satoshi Kawashima, Sawako Tomatsuri, Yukari Nagasaka, Hiroshi Yoshida, Ryunosuke Machida, Akihiro Hirakawa, Kenichi Nakamura, Kan Yonemori
Publikováno v:
Journal of Clinical Oncology. 41:2789-2799
PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) exp
Autor:
Haruyasu Murakami, Seiji Niho, Yukari Nagasaka, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Toshiyuki Kozuki, Yusuke Okuma, Jun Sato, Shoichi Itoh, Mamiko Kawasaki, Noboru Yamamoto, Tomoaki Yamada, Kenichi Nakamura, Yasuhito Fujisaka, Miyako Satouchi, Hidenori Mizugaki
Publikováno v:
The Lancet. Oncology. 21(6)
Thymic carcinoma is a rare malignant disease and standard treatment for advanced or metastatic thymic carcinoma previously treated with platinum-based chemotherapy has not been established. Lenvatinib is a novel multi-targeted inhibitor of VEGFR, FGF
Autor:
Ryunosuke Machida, Yasuhito Fujisaka, Mamiko Kawasaki, Jun Sato, Noboru Yamamoto, Hidenori Mizugaki, Tomoaki Yamada, Yuichiro Ohe, Toshiyuki Kozuki, Yukari Nagasaka, Shoichi Itoh, Haruyasu Murakami, Seiji Niho, Kenichi Nakamura, Miyako Satouchi, Yusuke Okuma, Aya Kuchiba
Publikováno v:
SSRN Electronic Journal.
Background: Thymic carcinoma is a rare malignant disease, and standard treatment for advanced/metastatic thymic carcinoma previously treated with platinum-based chemotherapy has not been established. Several multi-targeted inhibitors have demonstrate
Autor:
Gakuto Ogawa, Yoshitaka Honma, Mamiko Kawasaki, Kenichi Nakamura, Satoru Iwasa, Hirokazu Shoji, Mikio Mori, Ken Kato, Atsuo Takashima, Y. Yamada, Narikazu Boku, Aya Kuchiba, Natsuko Okita
Publikováno v:
Journal of Clinical Oncology. 37:3538-3538
3538 Background: Although regorafenib significantly improved overall survival compared with placebo for patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapies in the global phase III CORRECT trial, regorafenib is ofte
Publikováno v:
Archives of toxicology. 80(6)
Hepatic drug metabolism is impaired in experimental animals and humans with renal diseases. An anticancer drug, cisplatin induces acute renal failure (ARF) in rats. Under the same experimental conditions, cisplatin causes down-regulation of hepatic c
Publikováno v:
Archives of Toxicology; Jun2006, Vol. 80 Issue 6, p347-353, 7p, 6 Graphs